Cargando…
Prolonged survival with systemic chemotherapy in an advanced malignant mesothelioma: A case report
Peritoneal mesotheliomas are very rare tumors. Their prognosis is poor, average survival does not exceed 1 year after peritoneal cytoreduction. Systemic chemotherapy is considered to have no proven value in the management of peritoneal mesotheliomas. Objective responses with systemic chemotherapy ar...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874336/ https://www.ncbi.nlm.nih.gov/pubmed/33613924 http://dx.doi.org/10.1177/2036361320984527 |
_version_ | 1783649571755261952 |
---|---|
author | Elghali, Mohamed Amine Bourigua, Rym Belaid, Imtinene Nasri, Salsabil Mestiri, Sara Yaacoub, Sara Makni, Amine Letaief, Rached |
author_facet | Elghali, Mohamed Amine Bourigua, Rym Belaid, Imtinene Nasri, Salsabil Mestiri, Sara Yaacoub, Sara Makni, Amine Letaief, Rached |
author_sort | Elghali, Mohamed Amine |
collection | PubMed |
description | Peritoneal mesotheliomas are very rare tumors. Their prognosis is poor, average survival does not exceed 1 year after peritoneal cytoreduction. Systemic chemotherapy is considered to have no proven value in the management of peritoneal mesotheliomas. Objective responses with systemic chemotherapy are very rare. We report here a case of an advanced peritoneal mesothelioma which achieved an unexpected partial response with chemotherapy, allowing the patient to have a right colectomy. The patient was referred to a specialized center on HIPEC, but taking in account the long awaiting interval, the HIPEC was judged to be inefficient and then the poursuit of 6 cycles of systemic chemotherapy was decided. The patient is still alive without any symptom and with a good performance status at 59 months after diagnosis. Throughout our case, we provide an encouraging evidence of the role of initial systemic chemotherapy in the downstaging of initially unresectable primary malignant mesothelioma and in the improvement of overall survival. |
format | Online Article Text |
id | pubmed-7874336 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-78743362021-02-19 Prolonged survival with systemic chemotherapy in an advanced malignant mesothelioma: A case report Elghali, Mohamed Amine Bourigua, Rym Belaid, Imtinene Nasri, Salsabil Mestiri, Sara Yaacoub, Sara Makni, Amine Letaief, Rached Rare Tumors Case Report Peritoneal mesotheliomas are very rare tumors. Their prognosis is poor, average survival does not exceed 1 year after peritoneal cytoreduction. Systemic chemotherapy is considered to have no proven value in the management of peritoneal mesotheliomas. Objective responses with systemic chemotherapy are very rare. We report here a case of an advanced peritoneal mesothelioma which achieved an unexpected partial response with chemotherapy, allowing the patient to have a right colectomy. The patient was referred to a specialized center on HIPEC, but taking in account the long awaiting interval, the HIPEC was judged to be inefficient and then the poursuit of 6 cycles of systemic chemotherapy was decided. The patient is still alive without any symptom and with a good performance status at 59 months after diagnosis. Throughout our case, we provide an encouraging evidence of the role of initial systemic chemotherapy in the downstaging of initially unresectable primary malignant mesothelioma and in the improvement of overall survival. SAGE Publications 2021-02-04 /pmc/articles/PMC7874336/ /pubmed/33613924 http://dx.doi.org/10.1177/2036361320984527 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Case Report Elghali, Mohamed Amine Bourigua, Rym Belaid, Imtinene Nasri, Salsabil Mestiri, Sara Yaacoub, Sara Makni, Amine Letaief, Rached Prolonged survival with systemic chemotherapy in an advanced malignant mesothelioma: A case report |
title | Prolonged survival with systemic chemotherapy in an advanced malignant mesothelioma: A case report |
title_full | Prolonged survival with systemic chemotherapy in an advanced malignant mesothelioma: A case report |
title_fullStr | Prolonged survival with systemic chemotherapy in an advanced malignant mesothelioma: A case report |
title_full_unstemmed | Prolonged survival with systemic chemotherapy in an advanced malignant mesothelioma: A case report |
title_short | Prolonged survival with systemic chemotherapy in an advanced malignant mesothelioma: A case report |
title_sort | prolonged survival with systemic chemotherapy in an advanced malignant mesothelioma: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874336/ https://www.ncbi.nlm.nih.gov/pubmed/33613924 http://dx.doi.org/10.1177/2036361320984527 |
work_keys_str_mv | AT elghalimohamedamine prolongedsurvivalwithsystemicchemotherapyinanadvancedmalignantmesotheliomaacasereport AT bouriguarym prolongedsurvivalwithsystemicchemotherapyinanadvancedmalignantmesotheliomaacasereport AT belaidimtinene prolongedsurvivalwithsystemicchemotherapyinanadvancedmalignantmesotheliomaacasereport AT nasrisalsabil prolongedsurvivalwithsystemicchemotherapyinanadvancedmalignantmesotheliomaacasereport AT mestirisara prolongedsurvivalwithsystemicchemotherapyinanadvancedmalignantmesotheliomaacasereport AT yaacoubsara prolongedsurvivalwithsystemicchemotherapyinanadvancedmalignantmesotheliomaacasereport AT makniamine prolongedsurvivalwithsystemicchemotherapyinanadvancedmalignantmesotheliomaacasereport AT letaiefrached prolongedsurvivalwithsystemicchemotherapyinanadvancedmalignantmesotheliomaacasereport |